Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | USP4 | Q13107 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 2/20 | 0.31 |
| ▸ | WDR5 | P61964 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411697 | 0.81 | AR (0.39) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL16707448 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL4677321 | 0.77 | CYP3A4 (0.41) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL16707446 | 0.73 | ALDH1A1 (0.38) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL16707458 | 0.71 | TSHR (0.41) | ALDH1A1MAPTHTTTSHR | |
| SCHEMBL16707508 | 0.71 | ALDH1A1 (0.40) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL7624581 | 0.70 | ALDH1A1 (0.38) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL16707460 | 0.70 | USP2 (0.36) | ALDH1A1MAPTHTTUSP2USP8 | |
| SCHEMBL21396282 | 0.69 | APP (0.43) | ALDH1A1MAPTTSHRKDM4ENPC1 | |
| SCHEMBL21577619 | 0.69 | ALDH1A1 (0.42) | ALDH1A1MYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| US-5430060-A | Aldose reductase inhibitor | ZENECA LIMITED (GB) | 1995-07-04 | — | — | US | disclosed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | ALDH1A1 48/4885MAPT 121/4885HTT 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.